Search
Pluri Inc
PLURAdd to Watchlist
2.110USD
-0.030-1.44%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
22.01MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-1.44%
5 Days
+3.87%
1 Month
-11.34%
6 Months
-29.43%
Year to Date
-29.43%
1 Year
-63.50%
Key Figures
2.110Open
2.140High
2.22KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.02%Turnover Ratio
2.090Prev. Close
2.110Low
3.23KTurnover
LossP/E Static
-1.18P/B
0.00%Div Yield TTM
-84.91%ROA
5.96052wk High
0.55Volume Ratio
-22.58MNet Profit
10.43MShares
-2.9077EPS TTM
0.66Beta
-1205.58%ROE
2.22052wk Low
1.44%Amplitude
33.53%Gross Margin
22.01MMarket Cap
-3.19Reward/Risk
3.82%Risk Rate
TradingKey Stock Score of Pluri Inc
Currency: USD Updated: 2026-07-02Key Insights
Pluri Inc's fundamentals are relatively weak, and its growth potential is significant.Its valuation is considered fairly valued, ranking 242 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as , with the highest price target at 12.00.In the medium term, the stock price is expected to trend down.The company has shown weak stock market performance over the past month, in line with its weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Pluri Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Pluri Inc Highlights
StrengthsRisks
Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 365.51% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 1.34M.
Overvalued
The company’s latest PE is -0.73, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.35M shares, decreasing 3.15% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Analyst Rating
Based on
0
analysts
--
Current Rating
12.000
Target Price
+397.93%
Upside Space
Pluri Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Pluri Inc Info
Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.
Ticker SymbolPLUR
CompanyPluri Inc
CEOYanay (Yaky)
Websitehttps://pluri-biotech.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Pluri Inc (PLUR)?
The current price of Pluri Inc (PLUR) is 2.11.
What is the symbol of Pluri Inc?
The ticker symbol of Pluri Inc is PLUR.
What is the 52-week high of Pluri Inc?
The 52-week high of Pluri Inc is 5.96.
What is the 52-week low of Pluri Inc?
The 52-week low of Pluri Inc is 2.22.
What is the market capitalization of Pluri Inc?
The market capitalization of Pluri Inc is 22.01M.
What is the Earnings Per Share (EPS TTM) of Pluri Inc (PLUR)?
The Earnings Per Share (EPS TTM) of Pluri Inc (PLUR) is -3.56.